Theuer says the FDA has agreed with its proposals regarding key elements of the pivotal ENVASARC trial for envafolimab in the soft tissue sarcoma subtypes of undifferentiated pleomorphic sarcoma and myxofibrosarcoma.
TRACON Pharmaceuticals 'very pleased' with envafolimab pre-IND meeting with FDA
Quick facts: TRACON Pharmaceuticals
Price: 2.3 USD
Market Cap: $12.65 m
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...
In exchange for publishing services rendered by the Company on behalf of TRACON Pharmaceuticals named herein, including the promotion by the Company of TRACON Pharmaceuticals in any Content on the Site, the Company...FOR OUR FULL DISCLAIMER CLICK HERE